1McCredie J,Willert HG. Longitudinal limb deficiencies and the sclerotomes.potential uses and limitations.An analysis of 378 dysmelic malformations induced by thalidomide.J Bone Joint Surg Br, 1999,81:9～23
2Corral LG.Kaplan G,Immunomodulation by Thalidomide and Thalidomide analogues.Ann Rheum Dis,1999,58(Suppl 1): 1107～1113
3Haslett PA, Corral LG, Albert M, et al.Thalidomide costimulates primary human T lymphocytes,preferentially inducing proliferation,cytokine production,and cytotosic responses the CD8+subset.J ExpMed, 1998,187:1885～1892
4kruse FE ,Joussen AM ,Rohrschneider K,et al. Thalidomide inhibits corneal angiogenesis induced by vascular endotelial growth factor[J].Graefes arch Clin Exp0phslmol, 1998,236(6):461～466
5Stephens TD,Bunde CJ,Fillmore BJ.Mdchanidm of action in Thalidomide teratogenesis. Biochem Pharmacol, 2000,59:1489～1499
6Parman T,Wiley MJ,Wells PG.Free tadical-mediated oxidative DNA damage in the mechanism of Thalidomide teratogenicity. Nat Med, 1999,(5):582～585
7Thiele A,Thormann M,Hofman Hj ,et al.A possible tole of N-cadherin in Thalidomide teratogenicity.Life Sci, 2000,67(4):457～461
8Meierhofer c,Dunzendorfer S,Wiedermann CJ.Protein Kinase Cdependent effects on leukocyte migration of thalidomide.J Infect Dis,1999,180:216～219
10Rajkumar SV,Gertz MA,Lacy MQ,et al.Thalidomide as initial therapy for early stage myeloma. Leukemia, 2003Apr, 17(4):775～9
二级参考文献30
1Kerbel RS. Tumor angiogenesis: past, present and the near future.Carcinogenesis,2000;21:505～515
2Slodkowska J,Sikora J,Roszkowski-Sliz K,et al.Expression of vascular endothelial growth factor and basic fibroblast growth factor receptors in lung cancer. Analyt Quant Cytol Histol, 2000; 22: 398～402
3DAmato RK,Loughman MS,Flynn E.Thalidomide is an inhibitor of angiogenesis.Proc Natl Acad Sci USA,1994;91:4082～4085
4Rajkumar SV,Leong T,Fonseca R,et al.Bone marrow angiogenesis has prognostic value in multiple myeloma:an Eastern Cooperative Oncology Group Study.Proguam Proc Am Soc Clin Oncol,1999;18:68
5Munshi N,Wilson CS,Penn K,et al.Angiogenesis in newly diagnosed multiple myeloma:poor progmosis with increases microvessel density(MVD) in bone marrow biopsies.Blood,1998;92:400
6Gupta S,Aggarwal S,Nakamura S.A possible role of multidrug resistance-associated protein(MRP) in basic fibroblast growth factor secretion by AIDS-associated Kaposis sarcoma cells:Asurvival molecule?J Clin Immuno,1998;18:256～263
2Renller,A, Roanan,P,Hardan I et al therary with thalidomide in refractory mutiple myeloma Patientsthe revial of an olddray Br J Henatol,2000,108(2):391.
3Rajkumar SV Gertz MA ,Lacy MQ, et al.Thalidomide as initial therapy for early stage myeloma. Leukemia,2003Apr,17(4):775 ～9.
4Fernandez LP,schlegel PG,Bakerj.et .al. Does thalidomide affect IL-2 response and production? Exp Hematol,1995,23(9):978.
5Singhal S. Mehtaj,Desikan Retal Anti-tumor activity of thalidomide in refractory Multiple Myeloma, N Engl J Med 1999,341(1):1565.
